Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ACOSOG-Z4032||ACSOG||A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection Plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC); 3 cm or Smaller||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z4099||ACSOG||A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)<br><br>||Adult CIRB - Late Phase Emphasis||Completed|
|ACOSOG-Z6051||ACSOG||A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resection Versus Open Resection for Rectal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z9031||ACSOG||A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients with Retroperitoneal Sarcomas (RPS)||Adult CIRB - Late Phase Emphasis||Completed|
|ACOSOG-Z1031||ACSOG||A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily); Letrozole (2.5 mg); or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z1041||ACSOG||A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011203||Alliance||A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic; Estrogen Receptor Positive; HER2 Negative Breast Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|A081105||Alliance||Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A151216||Alliance||Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031501||Alliance||Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation||Adult CIRB - Late Phase Emphasis||Available to Open|